TY - JOUR
T1 - Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma
T2 - a multicenter study
AU - Shoda, Junichi
AU - Matsuda, Atsushi
AU - Shida, Takashi
AU - Yamamoto, Masakazu
AU - Nagino, Masato
AU - Tsuyuguchi, Toshio
AU - Yasaka, Takahiro
AU - Tazuma, Susumu
AU - Uchiyama, Kazuhisa
AU - Unno, Michiaki
AU - Ohkohchi, Nobuaki
AU - Nakanuma, Yasuni
AU - Kuno, Atsushi
AU - Narimatsu, Hisashi
N1 - Funding Information:
This work was supported in part by a Grant-in-aid from the National Survey for Intractable Hepatobiliary Diseases from the Ministry of Health, Labour and Welfare, Japan, and a Grant-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (Nos. 24390323 and 15K10197).
Publisher Copyright:
© 2016, The Author(s).
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Background: Wisteria floribunda agglutinin (WFA)-sialylated mucin core polypeptide 1 (MUC1) was investigated as a new glycoprotein marker for cholangiocarcinoma (CC) using glycoproteomics technologies. In this multicenter study, WFA-sialylated MUC1 levels in serum and bile samples were measured to determine their diagnostic capability in biliary tract carcinoma (BTC) and intrahepatic (Ih) CC. Methods: The study included 244 patients with BTC, 59 patients with IhCC, 287 patients with benign biliary tract diseases, and 44 control subjects. Results: Serum WFA-sialylated MUC1 levels were significantly higher in patients with either BTC or IhCC than in control subjects and those with benign biliary tract diseases. Patients with IhCC showed higher WFA-sialylated MUC1 levels than patients with tumors at other sites. No significant differences in WFA-sialylated MUC1 levels were found with regard to cancer stage or tissue type. Receiver operating characteristic curve analysis showed that WFA-sialylated MUC1 was superior to carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) for the diagnosis of benign biliary tract diseases, BTC, and IhCC, as well as for stage I and II carcinomas. Significantly higher levels of biliary WFA-sialylated MUC1 were observed in BTC/IhCC than in benign biliary tract diseases. The diagnostic capability of biliary WFA-sialylated MUC1 was also superior to that of CA19-9, and diagnostic sensitivity was higher than that of biliary cytology for BTC/IhCC. Conclusions: WFA-sialylated MUC1 is a useful novel biomarker for BTC/IhCC. In the future, this measurement should be applied in the clinical setting.
AB - Background: Wisteria floribunda agglutinin (WFA)-sialylated mucin core polypeptide 1 (MUC1) was investigated as a new glycoprotein marker for cholangiocarcinoma (CC) using glycoproteomics technologies. In this multicenter study, WFA-sialylated MUC1 levels in serum and bile samples were measured to determine their diagnostic capability in biliary tract carcinoma (BTC) and intrahepatic (Ih) CC. Methods: The study included 244 patients with BTC, 59 patients with IhCC, 287 patients with benign biliary tract diseases, and 44 control subjects. Results: Serum WFA-sialylated MUC1 levels were significantly higher in patients with either BTC or IhCC than in control subjects and those with benign biliary tract diseases. Patients with IhCC showed higher WFA-sialylated MUC1 levels than patients with tumors at other sites. No significant differences in WFA-sialylated MUC1 levels were found with regard to cancer stage or tissue type. Receiver operating characteristic curve analysis showed that WFA-sialylated MUC1 was superior to carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) for the diagnosis of benign biliary tract diseases, BTC, and IhCC, as well as for stage I and II carcinomas. Significantly higher levels of biliary WFA-sialylated MUC1 were observed in BTC/IhCC than in benign biliary tract diseases. The diagnostic capability of biliary WFA-sialylated MUC1 was also superior to that of CA19-9, and diagnostic sensitivity was higher than that of biliary cytology for BTC/IhCC. Conclusions: WFA-sialylated MUC1 is a useful novel biomarker for BTC/IhCC. In the future, this measurement should be applied in the clinical setting.
KW - Biliary tract carcinoma
KW - Biomarker
KW - Glycoproteomics
KW - Intrahepatic cholangiocarcinoma
KW - Multicenter study
UR - http://www.scopus.com/inward/record.url?scp=84976412698&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976412698&partnerID=8YFLogxK
U2 - 10.1007/s00535-016-1230-0
DO - 10.1007/s00535-016-1230-0
M3 - Article
C2 - 27358229
AN - SCOPUS:84976412698
SN - 0944-1174
VL - 52
SP - 218
EP - 228
JO - Journal of gastroenterology
JF - Journal of gastroenterology
IS - 2
ER -
